Tricida IncChange company Symbol lookupSelect an option...TCDAQ Tricida IncDDOG Datadog IncCLX Clorox CoATTO Atento SATOWN TowneBankCHWY Chewy IncO Realty Income CorpHOOK HOOKIPA Pharma IncAI C3.ai IncQSG QuantaSing Group LtdGo
Change company Symbol lookup
Select an option...
TCDAQ Tricida Inc
DDOG Datadog Inc
CLX Clorox Co
ATTO Atento SA
TOWN TowneBank
CHWY Chewy Inc
O Realty Income Corp
HOOK HOOKIPA Pharma Inc
AI C3.ai Inc
QSG QuantaSing Group Ltd
Health Care : Pharmaceuticals | Small Cap Value
Company profileTricida, Inc. is a pharmaceutical company. The Company is focused on its investigational drug candidate, veverimer (TRC101). TRC101 is a non-absorbed, orally administered polymer designed to treat metabolic acidosis and slow CKD progression by binding and removing acid from the gastrointestinal (GI) tract. Its veverimer, is a low-swelling, spherical polymer bead that is approximately 100 micrometers in diameter, which is a single, molecular weight, crosslinked polyamine molecule. Veverimer is a single, high molecular weight, crosslinked polyamine molecule. The size of veverimer prevents systemic absorption from the GI tract. The high degree of cross-linking within veverimer limits swelling and the overall volume in the GI tract, with the goal of facilitating GI tolerability. It is conducting renal outcomes clinical trial, VALOR-CKD (TRCA-303), to determine if veverimer slows CKD progression in patients with metabolic acidosis associated with CKD.
|
|
|
|
| |
| Latest Earnings Beat Consensus (Q3 ending 09/2022) | Next Earnings Announcement | ||||||
|---|---|---|---|---|---|---|---|
| Q3 Non-GAAP earnings GAAP vs. Non-GAAP EarningsTD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts. Announced November 14, 2022 | -$0.44 | Q3 Consensus of 3 analysts | -$0.54 | Difference from consensus | 19.12% | Q4 Earnings will announce | -- |
Quarterly Earnings History and Estimates
Hide high-low estimates
Draw trendlines
Draw up to 3 lines inside the chart.
TCDAQ's fiscal year ends in December
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.
Information provided by Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.